uniQure Inc.: uniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-existing Antibodies to AAV5 Vector
~ Further Supports Potential for AAV5 Gene Therapies to be Viable Treatments in Nearly All Patients
~ Data Presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting ~
LEXINGTON, Mass. and AMSTERDAM, May 13, 2021showing clinical benefit in hemophilia B patients with pre-existing neutralizing antibodies (NAbs) to AAV5, and no relationship between AAV5 NAbs and the tolerability of the therapy.
The data were featured on Wednesday, May 12, 2021 at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in an oral presentation by Michael Recht, M.D., Ph.D., M.B.A., professor of pediatrics, division of hematology and oncology at the Oregon Health & Science University School of Medicine. These data were previously presented at a medical meeting late last year.
uniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-existing Antibodies to AAV5 Vector streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
~ Further Supports Potential for AAV5 Gene Therapies to be Viable Treatments in Nearly All Patients
~ Data Presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting ~
LEXINGTON, Mass. and AMSTERDAM, May 13, 2021 (GLOBE NEWSWIRE) uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, yesterday presented 26-week clinical data from the pivotal, Phase III HOPE-B gene therapy trial of etranacogene dezaparvovec showing clinical benefit in hemophilia B patients with pre-existing neutralizing antibodies (NAbs) to AAV5, and no relationship between AAV5 NAbs and the tolerability of the therapy.
The data were featured on Wednesday, May 12, 2021 at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in an oral presentation by Michael Recht, M.D., Ph.D., M.B.A., professor of pediatrics, division of hematology and oncology at the Oregon Health & Science University School
ORIC Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update
Lead program ORIC-101 on track for two initial Phase 1b data readouts in 2021
Three IND/CTA filings for ORIC-533, -944, and -114 expected in 2021
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter ended March 31, 2021.
“We continue to make steady progress in advancing our robust pipeline of novel oncology candidates,” said Jacob Chacko, M.D., president and chief executive officer. “As planned, we will present preliminary safety, pharmacokinetic, and translational data, as well as early efficacy data from our ongoing Phase 1 trial of ORIC-101 in combination with nab-paclitaxel in solid tumors at the upcoming ASCO Annual Meeting. In
NEWSru com :: Главред The Insider рассказал о допросе в Шереметьево, странных вопросах и изъятии гаджетов newsru.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newsru.com Daily Mail and Mail on Sunday newspapers.